Open-Label Study Assessing Relative And Absolute Bioavailability Of Oral Camizestrant Formulations And Food Effects In Healthy Postmenopausal Women

By Andy Sykes, Helena Engman, Nigel Taylor, Tim Brier, Rhiannon Maudsley, Bistra Kirova, Alastair M. Mathewson, Ryan A. Bragg, Malin Gränfors, Eric T. Gangl, Teresa Klinowska, Yan Li, Somasekhar R. Menakuru, Chris Roe, John McDermott, Justin P. O. Lindemann

© 2026 AstraZeneca. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. This is an open access article.

Ensuring consistent therapeutic exposure is critical during late-stage drug development, especially when manufacturing processes evolve to meet scale-up needs. Recent investigations into oral camizestrant—a next-generation selective estrogen receptor degrader (SERD)—confirm that its pharmacokinetic profile remains stable across different tablet formulations. This stability provides essential flexibility, ensuring that advancements in manufacturing technology do not alter the drug's performance in clinical settings.

Equally vital is the discovery that food intake does not significantly impact how the body absorbs this therapy. Whether administered in a fasted state or with a high-fat meal, the systemic exposure remains consistent. This lack of food effect simplifies treatment for patients, allowing for more convenient dosing schedules and easier integration with other medications that may have their own dietary restrictions. Understanding these foundational pharmacology insights is key to optimizing treatment protocols for hormone receptor-positive breast cancer. Read the full study to explore the complete data on absolute bioavailability and clinical safety.